245 related articles for article (PubMed ID: 30679799)
21. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
23. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
[TBL] [Abstract][Full Text] [Related]
24. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
25. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
O'Connor C; Lohan F; Campos J; Ohlsson E; Salomè M; Forde C; Artschwager R; Liskamp RM; Cahill MR; Kiely PA; Porse B; Keeshan K
Oncogene; 2016 Oct; 35(40):5272-5281. PubMed ID: 26996668
[TBL] [Abstract][Full Text] [Related]
26. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
[TBL] [Abstract][Full Text] [Related]
27. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
[TBL] [Abstract][Full Text] [Related]
28. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
29. C/EBPα dysregulation in AML and ALL.
Paz-Priel I; Friedman A
Crit Rev Oncog; 2011; 16(1-2):93-102. PubMed ID: 22150310
[TBL] [Abstract][Full Text] [Related]
30. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
31. A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse.
Schwieger M; Löhler J; Fischer M; Herwig U; Tenen DG; Stocking C
Blood; 2004 Apr; 103(7):2744-52. PubMed ID: 14656889
[TBL] [Abstract][Full Text] [Related]
32. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
[TBL] [Abstract][Full Text] [Related]
33. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.
Pulikkan JA; Dengler V; Peer Zada AA; Kawasaki A; Geletu M; Pasalic Z; Bohlander SK; Ryo A; Tenen DG; Behre G
Leukemia; 2010 May; 24(5):914-23. PubMed ID: 20376080
[TBL] [Abstract][Full Text] [Related]
34. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
Pulikkan JA; Peramangalam PS; Dengler V; Ho PA; Preudhomme C; Meshinchi S; Christopeit M; Nibourel O; Müller-Tidow C; Bohlander SK; Tenen DG; Behre G
Blood; 2010 Dec; 116(25):5638-49. PubMed ID: 20889924
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
37. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
38. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
39. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
40. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
